88014-15-7

Usage

Uses

Used in Neuropharmacology Research:
2-(3,4-Dihydro-1H-isoquinolin-2-yl)-ethanol is used as a research compound for studying its interactions with the central nervous system and its potential effects on neurological conditions. Its specific binding and modulation of neurotransmitter systems can provide insights into the development of new drugs targeting neurological disorders.
Used in Drug Development:
In the pharmaceutical industry, 2-(3,4-Dihydro-1H-isoquinolin-2-yl)-ethanol serves as a starting point for the development of new drugs. Its unique chemical structure and biological activity make it a valuable template for designing and optimizing compounds with therapeutic potential for the treatment of central nervous system disorders.
Used in Chemical Synthesis:
2-(3,4-Dihydro-1H-isoquinolin-2-yl)-ethanol is also used as a synthetic intermediate in the preparation of various isoquinoline-based compounds. Its versatile structure allows for further functionalization and modification, enabling the synthesis of a wide range of chemical entities with diverse applications in research and drug discovery.

InChI:InChI=1/C11H15NO/c13-8-7-12-6-5-10-3-1-2-4-11(10)9-12/h1-4,13H,5-9H2

Upstream product

• 75-21-8 oxirane 
• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 54423-94-8 2-(2-hydroxy-ethyl)-isoquinolinium; bromide 
• 94783-05-8 2-(2-Hydroxyethyl)-3,4-dihydroisochinoliniumbromid 
• 624-76-0 Iodoethanol 
• 540-51-2 2-bromoethanol 
• 95071-86-6 2,3,5,6-tetrahydro-10bH-oxazolo<2,3-a>isoquinoline 
• 18010-05-4 2-ethoxycarbonyl-methylisoquinolinium bromide 
• 119-65-3 isoquinoline 
• 88014-09-9 (3,4-dihydro-1H-isoquinolin-2-yl)-acetic acid ethyl ester 
• 107-07-3 2-chloro-ethanol 

Downstream Products

• 101728-74-9 2-[2-(3,4-dichloro-benzyloxy)-ethyl]-1,2,3,4-tetrahydro-isoquinoline 
• 101717-81-1 2-(2-benzyloxy-ethyl)-1,2,3,4-tetrahydro-isoquinoline 
• 101784-02-5 2-[2-(4-chloro-benzyloxy)-ethyl]-1,2,3,4-tetrahydro-isoquinoline 
• 102010-31-1 2-[2-(4-methoxy-benzyloxy)-ethyl]-1,2,3,4-tetrahydro-isoquinoline 
• 108839-62-9 2-[2-(2-methyl-benzyloxy)-ethyl]-1,2,3,4-tetrahydro-isoquinoline 
• 27160-30-1 2-(2-chloro-ethyl)-1,2,3,4-tetrahydro-isoquinoline; hydrochloride 

Relevant academic research and scientific papers

Iron oxide superparamagnetic nanocarriers bearing amphiphilic N-heterocyclic choline analogues as potential antimicrobial agents

Magnetic nanoparticles represent an advanced tool in biomedicine because they can be simultaneously functionalized and guided using a magnetic field. Iron oxide magnetic nanoparticles precoated with oleic acid and bearing novel antimicrobial N-heterocyclic choline analogues, namely O-, N- and O,N-bis-undecyl-substituted N-(2-hydroxyethyl)-1,2,3,4-tetrahydroisoquinolinium derivatives, have been obtained as potential biomedical agents for drug delivery and antimicrobial therapy. Structural and size determinations for the novel synthesized magnetic nanosystems were carried out based upon magnetogranulometry, dynamic light-scattering measurements and X-ray diffraction analysis. The most expected iron oxide core diameter was 6.2-10.5 nm. The magnetization analyses showed that the particles are superparamagnetic at room temperature. Aqueous magnetic fluids of the synthesized nanoparticles were examined in vitro concerning Gram-positive (Staphylococcus aureus MSCL 334, Bacillus cereus MSCL 330) and Gram-negative (Escherichia coli MSCL 332, Pseudomonas aeruginosa MSCL 331, Proteus mirabilis MSCL 590) bacterial strains and fungi (Candida albicans MSCL 378, Aspergillus niger MSCL 324). It was found that the samples have magnetic properties and possess antimicrobial activity. The minimum inhibitory concentration against S. aureus for the most active magnetic fluid was determined as 16 μg ml-1.

Silyl modification of biologically active compounds. 10. Lipid type organosilicon derivatives of 8-hydroxyquinoline and n-(2-hydroxyethyl)-1,2,3,4- tetrahydro(sila, iso)quinolines

Organosilicon alkylation of the primary alcoholic groups of N-(2-hydroxyalkyl) derivatives of 1,2,3,4-tetrahydroquinoline, tetrahydroisoquinoline, and 4,4-dimethyltetrahydro-4-silaisoquinoline, and also the hydroxyl group of 8-hydroxyquinoline by trialkyl

HETEROCYCLIC COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN

Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, especially huntingtin protein aggregation, compositions thereof, and methods of their use.

Diethyl Phosphite Promoted Electrochemical Oxidation of Tetrahydroisoquinolines to 3,4-Dihydroisoquinolin-1(2 H)-ones

A diethyl phosphite mediated electrochemical oxidation strategy for the synthesis of 3,4-dihydroisoquinolin-1(2 H)-ones from tetrahydroisoquinolines under mild conditions has been developed. This protocol provides an environmentally friendly and simple way for the construction of C=O bonds in an undivided cell unit.

Silyl modification of biologically active compounds. 13. Synthesis, cytotoxicity and antibacterial action of N-methyl-N-(2-triorganylsiloxyethyl)-1, 2,3,4-tetrahydro(iso)quinolinium iodides

A series of N-methyl-N-(2-triorganylsiloxyethyl)-1,2,3,4-tetrahydro(iso) quinolinium iodides has been synthesized via dehydrocondensation reaction of N-(2-hydroxyethyl)-1,2,3,4-tetrahydroisoquinoline, N-(2-hydroxyethyl)-1,2,3,4- tetrahydroquinoline and 4,4-dimethyl-N-(2-hydroxyethyl)-4-sila-1,2,3,4- tetrahydroisoquinoline with trialkyl(aryl)hydrosilanes and subsequent alkylation, and characterized by 1H, 13C and 29Si NMR and mass spectroscopy. The biological activity data exhibited a marked enhancement of inhibitory activity against tumour cell lines and almost all the test bacterial/fungal strains in comparison with their 2-hydroxyethyl precursors. Cytotoxicity in the microgram range against HT-1080 (human fibrosarcoma) and MG-22A (mouse hepatoma) cancer cell lines was observed for most of compounds. Copyright

MEDICAMENTS

A compound of formula (I) is described: wherein R1 and R2 are as defined in the text and wherein the compounds are intended for use in treating medical conditions characterized by an imbalance in dopamine receptor activity.

Electrooxidative cyclization of hydroquinolyl alcohols, hydroquinolylamines, and dimethyl aminomalonates

Several hydroquinolyl alcohols and amines were electrochemically oxidized in methanol in the presence of sodium methoxide and potassium iodide to afford the corresponding intramolecular cyclization products. Furthermore, several amino malonates were electrochemically oxidized to yield the corresponding heterocyclic compounds through an intramolecular carbon-carbon bond formation in the presence of sodium cyanide in methanol. CSIRO 2007.

Alkali metal-mediated synthesis of 1- and 4-substituted N-alkyl-1,2,3,4-tetrahydroisoquinolines

Reductive cleavage by electron transfer from Li or K metal of 1-alkoxy-substituted N-alkyltetrahydroisoquinolines led to the formation of organometallic derivatives. Quenching of these intermediates with electrophilic reagents afforded 1- or 4-substituted

QUINOLINE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS NEUROKININ 3 (NK-3) - AND NEUROKININ 2 (NK-3) RECEPTOR ANTAGONISTS

A compound of formula (I): or a salt thereof, or a solvate thereof, wherein, Ar is an optionally substituted aryl or a C5-7 cycloalkdienyl group, or an optionally substituted single or fused ring aromatic heterocyclic group; R is C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl, optionally substituted phenyl or phenyl C1-6 alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatoms selected from O and N, hydroxy C1-6 alkyl, amino C1-6 alkyl, C1-6 alkylaminoalkyl, di C1-6 alkylaminoalkyl, C1-6 acylaminoalkyl, C1-6 alkoxyalkyl, C1-6 alkylcarbonyl, carboxy, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonyl C1-6 alkyl, aminocarbonyl, C1-6 alkylaminocarbonyl, di C1-6 alkylaminocarbonyl, halogeno C1-6 alkyl; or R is a group--(CH2)p--wherein p is 2 or 3 which group forms a ring with a carbon atom of Ar; R1 represents hydrogen or up to four optional subtitutents selected from the list consisting of: C1-6 alkyl, C1-6 alkenyl, aryl, C1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino or mono-and di-C1-6 alkylamino; R2 represents hydrogen, C 1-6-alkyl, hydroxy, halogen, cyano, amino, mono-or di-C1-6-alkylamino, alkylsulphonylamino, mono-or di-C1-6-alkanoylamino wherein any alkyl group is optionally substituted with an amino group or with a mono-or di-alkylamino group, or R2 is a moiety--X--(CH2)n--Y wherein X is a bond or--O--and n is an integer in the range of from 1 to 5 providing that when X is--O--n is only an integer from 2 to 5 and Y represents a group NY1Y2 wherein Y1 and Y2 are independently selected from hydrogen, C1-6-alkyl, C1-6-alkenyl, aryl or aryl-C1-6-alkyl or Y is hydroxy, halogen or an optionally substituted N-linked single or fused ring, heterocyclic group, R3 is branched or linear C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring aromatic heterocyclic group; and R4 represents hydrogen or C1-6 alkyl; a process for the preparation of such a compound, a pharmaceutical compositon containing such a compound and the use of such a compound or composition in medicine.

α-amino acid phenolic ester derivatives: Novel water-soluble general anesthetic agents which allosterically modulate gabaa receptors

In the search for a novel water-soluble general anesthetic agent the activity of an α-amino acid phenolic ester lead, identified from patent literature, was markedly improved. In addition to improving in vivo activity in mice, good in vitro activity at GABAA receptors was also conferred. Within the series of compounds good enantioselectivity for both in vitro and in vivo activity was found, supporting a protein-mediated mechanism of action for anesthesia involving allosteric modulation of GABAA receptors. α-Amino acid phenolic ester 19, as the hydrobromide salt Org 25435, was selected for clinical evaluation since it retained the best overall anesthetic profile coupled with improved stability and water solubility. In the clinic it proved to be an effective intravenous anesthetic in man with rapid onset of and recovery from anesthesia at doses of 3 and 4 mg/kg.